tetano
Editor, Senior Moderator
Future Med Chem. 2014 May;6(7):757-74. doi: 10.4155/fmc.14.30.
From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs?
Cheng CK1, Tsai CH, Shie JJ, Fang JM.
Author information
Abstract
For the treatment of seasonal flu and possible pandemic infections the development of new anti-influenza drugs that have good bioavailability against a broad spectrum of influenza viruses including the resistant strains is needed. In this review, we summarize previous methods for the structural modification of zanamivir, a potent neuraminidase inhibitor that has rare drug resistance, in order to develop effective anti-influenza drugs. We also report recent research into the design of multivalent zanamivir drugs and bifunctional zanamivir conjugates, some of which have shown better efficacy in animal experiments. As a step towards developing improved antivirals, conjugating anti-influenza drugs with anti-inflammatory agents can improve oral bioavailability and also exert synergistic effect in influenza therapy.
PMID:
24941871
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/24941871
From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs?
Cheng CK1, Tsai CH, Shie JJ, Fang JM.
Author information
Abstract
For the treatment of seasonal flu and possible pandemic infections the development of new anti-influenza drugs that have good bioavailability against a broad spectrum of influenza viruses including the resistant strains is needed. In this review, we summarize previous methods for the structural modification of zanamivir, a potent neuraminidase inhibitor that has rare drug resistance, in order to develop effective anti-influenza drugs. We also report recent research into the design of multivalent zanamivir drugs and bifunctional zanamivir conjugates, some of which have shown better efficacy in animal experiments. As a step towards developing improved antivirals, conjugating anti-influenza drugs with anti-inflammatory agents can improve oral bioavailability and also exert synergistic effect in influenza therapy.
PMID:
24941871
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/24941871